Psoriatic Arthritis
Clinical Review
Biosimilars in Psoriasis: The Future or Not?
As patents for the biologic agents reach their expiration dates, dermatologists must prepare for the coming of biosimilars. These agents have been...
Practical Pearls
Clinical Pearl: Early Diagnosis of Nail Psoriasis and Psoriatic Arthritis
Psoriatic arthritis (PsA) is more common in patients with nail psoriasis. Radiograph imaging is a quick, inexpensive, and valuable diagnostic...
Conference Coverage
VIDEO: Interchangeability of biosimilars and parent compounds raise potential efficacy issues
WAILEA, Hawaii Biosimilars are coming to dermatology, but their impact from a clinical and insurance standpoint has yet to be determined,...
From the Journals
MTX side effects limit patient use
“Side effects alone or in combination with inadequate disease control were more important in the context of treatment discontinuation than...
Feature
FDA opens abbreviated approval pathway for interchangeable biosimilars
The FDA has proposed a regulatory path for biosimilar biologics that are interchangeable with the reference product.
Case Letter
Severe Henoch-Schönlein Purpura Complicating Infliximab Therapy for Ulcerative Colitis
Anti–tumor necrosis factor (TNF) α treatments have radically improved the management of chronic inflammatory conditions, including rheumatoid...
From the Journals
Bone fractures more likely to occur in psoriasis, PsA patients
This is the first population-based study to examine the relationship between bone fractures and psoriasis, according to the authors.
From the Journals
Symptoms don’t worsen during pregnancy in most PsA patients
Many patients benefit from better skin, although flares may come.
Conference Coverage
Fixed combination topical shows promise for psoriasis
MIAMI – The first study to evaluate a fixed-dose combination of a potent topical steroid combined with tazarotene evaluates multiple safety and...
From the Journals
Childhood psoriasis negatively impacts parental QOL
Parents of children with psoriasis experience significant negative quality-of-life issues, according to Dr. Megha Tollefson and her associates.
Feature
Medicare payments set for infliximab biosimilar Inflectra
Medicare will now cover payment for the infliximab biosimilar drug Inflectra.